SEC Comment Letter for Jasper Therapeutics, Inc. (JSPR, JSPRW) (CIK 0001788028) (JSPR) — Oct 13, 2022
Jasper Therapeutics, Inc. (JSPR, JSPRW) (CIK 0001788028)
Date: Oct. 13, 2022 · CIK: 0001788028 · Accession: 0000000000-22-011268
AI Filing Summary & Sentiment
File numbers found in text: 333-267777
Letter
United States securities and exchange commission logo October 13, 2022 Mr. Ronald Martell President and Chief Executive Officer Jasper Therapeutics, Inc. 2200 Bridge Pkwy Suite #102 Redwood City, CA 94065 Re:Jasper Therapeutics, Inc. Registration Statement on Form S-3 Filed October 7, 2022 File No. 333-267777 Dear Mr. Ronald Martell: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jimmy McNamara at 202-551-7349 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jeffrey T. Hartlin
Show Raw Text
United States securities and exchange commission logo
October 13, 2022
Mr. Ronald Martell
President and Chief Executive Officer
Jasper Therapeutics, Inc.
2200 Bridge Pkwy Suite #102
Redwood City, CA 94065
Re:Jasper Therapeutics, Inc.
Registration Statement on Form S-3
Filed October 7, 2022
File No. 333-267777
Dear Mr. Ronald Martell:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jimmy McNamara at 202-551-7349 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Jeffrey T. Hartlin